Genetic Mutation Analysis in Small Cell Lung Cancer by a Novel NGS-Based Targeted Resequencing Gene Panel and Relation with Clinical Features

<div>Study overview: (a) sequencing and analytical pipeline; (b) total mutations and number of genes per patient arranged according to clinical stages I, II, and III; (c) mutation counts of top 5% SCLC-related mutated genes observed in 90% of patients and 6 genes associated with NSE and clinical stage, where mutation to same gene is counted once (top) with their individual and combined summary of transition (Ti) and transversion (Tv) mutations (bottom); (d) mutational landscape of SCLC showing the number of coding somatic mutations per megabase of DNA (top) and a matrix of 20 frequently mutated genes colored by the type of variation (bottom).</div>

BioMed Research International

fig1

Figure 1

Figure 1: Genetic Mutation Analysis in Small Cell Lung Cancer by a Novel NGS-Based Targeted Resequencing Gene Panel and Relation with Clinical Features 

Figure 1 | Genetic Mutation Analysis in Small Cell Lung Cancer by a Novel NGS-Based Targeted Resequencing Gene Panel and Relation with Clinical Features 